- TETRAZOLINONE COMPOUND AND APPLICATION OF SAME
-
A tetrazolinone compound represented by formula (1): wherein R1 represents a C1-C3 alkyl group optionally having a fluorine atom, etc.; R2 and R4 represents a hydrogen atom, etc.; R3 represents a hydrogen atom,
- -
-
Paragraph 0468-0469
(2016/04/19)
-
- Tetrazolinone compound and application of same
-
The tetrazolinone compound according to the present invention, represented by formula (1) (In formula (1), R1 represents a C1-3 alkyl group which may have a fluorine atom, or the like; R2 and R4 represent a hydrogen atom or the like; R3 represents a hydro
- -
-
Paragraph 0939; 0940; 0941; 0942
(2016/10/08)
-
- TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF
-
Disclosed is a tetrazolinone compound having a high pest control effect and represented by the formula (1): wherein R1, R2, R3, and R11 each represent a halogen atom, a C1-C6 alkyl group, or the like; R4 and R5 each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, or the like; R6 represents a C1-C3 alkyl group which may have a halogen atom(s) or the like; R7, R8, and R9 each represent a hydrogen atom, a halogen atom, or the like; R10 represents a C1-C3 alkyl group or the like; R12 represents a C1-C6 alkyl group, a C3-C6 cycloalkyl group, or the like, and R13 represents a C1-C6 alkyl group, a C2-C6 alkenyl group, or the like.
- -
-
Paragraph 0834
(2015/11/24)
-
- Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists
-
A novel series of thaizole and oxazole containing phenoxy acetic acid derivatives is reported as PPAR-pan agonists. Incorporation of structurally constrained oxime-ether based linker in the chemotype of a potent PPARδ selective agonist GW-501516 was adapted as designing strategy. In vitro, selected test compounds 12a, 12c, 17a and 18a showed PPAR-pan agonists activities and among these four compounds tested, 12a emerged as highly potent and efficacious compound, while 17a exhibited moderate and balanced PPAR-pan agonistic activity. In vivo, selected test compounds 12a and 17a exhibited significant anti-hyperglycemic and anti-hyperlipidemic activities in relevant animal models. These results support our hypothesis that the introduction of structurally constrained oxime-ether linker between lipophilic tail and acidic head plays an important role in modulating subtype selectivity and subsequently led to the discovery of potent PPAR-pan agonists.
- Makadia, Pankaj,Shah, Shailesh R.,Pingali, Harikishore,Zaware, Pandurang,Patel, Darshit,Pola, Suresh,Thube, Baban,Priyadarshini, Priyanka,Suthar, Dinesh,Shah, Maanan,Giri, Suresh,Trivedi, Chitrang,Jain, Mukul,Patel, Pankaj,Bahekar, Rajesh
-
experimental part
p. 771 - 782
(2011/03/18)
-
- Ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit-Potential anti-metastatic drugs
-
A series of ethacrynic acid analogues, lacking the α,β-unsaturated carbonyl unit, was synthesized and subsequently evaluated for their ability to inhibit the migration of human breast cancer cells, MCF-7/AZ. Several of the analogues were already active in the low micromolar range, whereas ethacrynic acid itself shows no potential to inhibit the migration of these cancer cells. Preliminary studies show that the presence of one or more methoxy groups at the phenyl ring of ethacrynic acid is important in order for the ethacrynic acid analogues to demonstrate an inhibitory effect on the migration.
- Janser, Romy F.J.,Meka, Ranjith K.,Bryant, Zack E.,Adogla, Enoch A.,Vogel, Elizabeth K.,Wharton, Jaimie L.,Tilley, Cynthia M.,Kaminski, Catherine N.,Ferrey, Seth L.,Van slambrouck, Severine,Steelant, Wim F.A.,Janser, Ingo
-
experimental part
p. 1848 - 1850
(2010/07/06)
-
- A comparative study: One pot synthesis of some prochiral ketones using conventional and microwave assisted methods
-
Polyphosphoric acid (PPA) has been used to synthesize a number of prochiral aryl ketones as well as α,β-unsaturated diaryl ketones by conventional and microwave assisted methods in moderate to good yield. The microwave assisted method is advantageous due to increased yield and high purity of products within incredible short period of time.
- Salokhe,Mote,Suryavanshi,Salunkhe
-
experimental part
p. 1347 - 1351
(2010/07/05)
-
- Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone-A potent NR2B-selective N-methyl d-aspartate (NMDA) antagonist for the treatment of pain
-
(-)-6-[2-[4-(3-Fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone was identified as an orally active NR2B-subunit selective N-methyl-d-aspartate (NMDA) receptor antagonist. It has very high selectivity for NR2B subunits c
- Kawai, Makoto,Ando, Kazuo,Matsumoto, Yukari,Sakurada, Isao,Hirota, Masako,Nakamura, Hiroshi,Ohta, Atsuko,Sudo, Masaki,Hattori, Kazunari,Takashima, Tadashi,Hizue, Masanori,Watanabe, Shuzo,Fujita, Isami,Mizutani, Mayumi,Kawamura, Mitsuhiro
-
p. 5558 - 5562
(2008/04/07)
-
- Amide bridged piphenyl or biazaphenyl derivatives
-
This invention is concerned with compounds of the formula wherein one of R5, R6 and R7 is and R1 to R13, X1, X2, m and n are defined in the description, and all pharmaceutically
- -
-
Page/Page column 33
(2008/06/13)
-
- COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS
-
This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.
- -
-
-
- Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
-
PCT No. PCT/IB95/00380 Sec. 371 Date Feb. 13, 1996 Sec. 102(e) Date Feb. 13, 1996 PCT Filed May 18, 1995 PCT Pub. No. WO96/06081 PCT Pub. Date Feb. 29, 1996This invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein: (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7 and R5 is methyl or ethyl; or (b) R2 and R5 are taken together, forming a chroman-4-ol ring, and R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; and R6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo(3.2.1)octanyl derivative; provided that (a) when R2 and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and (b) when R2 and R5 are taken together, at least one of R1, R3 and R4 is not hydrogen; pharmaceutical compositions thereof; and methods of treating mammals suffering from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised with a compound of formula (I) hereinabove or a pharmaceutically acceptable salt thereof.
- -
-
-
- A REEXAMINATION OF THE RETRO-FRIES REARRANGEMENT OF SOME o-HYDROXYKETONES
-
The retro-Fries rearrangement, catalyzed by protic and Lewis acids, was studied for some o-hydroxyketones.The results are consistent with the mechanism of an heterolytic cleavage and rearrangement.It appears that, in general, Lewis acids do not induce the retro-Fries rearrangement of o-hydroxyketones.However, in certain cases, it may be brought about the presence of a protic acid generated in situ, from a solvent-catalyst interaction.
- Martin, Robert,Lafrance, Jean Ronald,Demerseman, Pierre
-
p. 539 - 548
(2007/10/02)
-